Digital dermoscopy monitoring in patients with multiple nevi: How many lesions should we monitor per patient?
To the Editor: Digital dermoscopy monitoring (DDM) of melanocytic lesions in patients with multiple nevi ([50 nevi) or atypical mole syndrome (AMS) have been demonstrated to increase early melanoma detection, while minimizing the unnecessary excision of benign lesions. 1 Several studies have investigated different follow-up protocols to determine the best strategy for optimizing clinical outcome and patient compliance. [2] [3] [4] [5] However, data are lacking, especially in the context of the number of lesions to monitor per patient. 2 We conducted an online survey among the 90 board members of the International Dermoscopy Society to determine current behaviors in the use of DDM. The questionnaire included 9 questions regarding (1) age; (2) gender; (3) work setting; (4) percentage of skin cancer patients seen per year; (5) number of primary melanomas diagnosed per year; (6) attitude for using DDM; (7) attitude for imaging all lesions or selected lesions; (8) number of selected lesions imaged; (9) use of total body photography (TBP).
Seventy-five board members (83.3%) participated in the survey. The majority (n ¼ 60, 80%) indicated that they perform DDM in patients with multiple nevi or AMS (Table I ). Among these, only 8 (13.3%) reported that they image all lesions in a given patient, whereas 52 (86.7%) reported that they select skin lesions for DDM, with almost 60% reporting that they image fewer than 10 lesions per patient. Interestingly, the great majority (n ¼ 56, 74.7%) of the interviewed members declared they use TBP. Moreover, 8 of the 15 participants (53.3%) who did not use a DDM, stated that they perform TBP.
To analyze factors influencing the decision to select or to monitor all lesions per patient, we used Spearman's rho coefficient to flag significant correlations, which were subsequently quantified via logistical regression. We expected that the decision to select lesions to monitor would depend on several factors, namely lack of time or increasing experience. All surveyed doctors were experienced dermoscopists, and no differences were found among those working in a private or in a public setting.
Monitoring attitude significantly correlated with age ( ¼ 0.274, P ¼ .034) and number of melanomas diagnosed each year ( ¼ 0.273, P ¼ .035). More specifically, older doctors tend to monitor all lesions, with 11% higher odds for each year of age added (OR ¼ 1.11, 95% CI 1.003-1.228, P ¼ .044). In contrast, doctors diagnosing more melanomas per year are more likely to select lesions to monitor. In detail, if the number of new melanomas per year is 11 to 30 or greater than 30, it is at least 9 times less likely that the physician will monitor all lesions (11-30, OR ¼ 0.111, 95% CI 0.013-0.970, P ¼ .047; [30, OR ¼ 0.097, 95% CI: 0.013-0.709, P ¼ .022).
In conclusion, this survey supports that DDM is a widely used method among clinicians dealing with patients with multiple nevi. Interestingly, the majority of respondents apply a combination of dermoscopy and TBP, underlying the importance of a combined approach when dealing with high-risk patients. The survey also highlighted the broad range of protocols in DDM. A study comparing the efficacy of the 2 monitoring approaches, namely DDM alone or DDM plus TBP, is needed in order to standardize the methodology and optimize patient care. 
